Phase 3 Trial of B-VEC, Topical Gene Therapy for DEB, Fully Enrolled
News
Krystal Biotech announced the full enrollment of a pivotal Phase 3 clinical trial of its topical gene therapy B-VEC (beremagene geperpavec) as a skin wound treatment for people with dystrophic epidermolysis bullosa (DEB). ... Read more